Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859495 · ClinicalTrials.gov registry record · Phase 2
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00859495 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 9 participants.
The verdict
NCT00859495, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous chemotherapy, and local P-32 irradiation for malignant pleural mesothelioma.
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Pemetrexed
- RADIATION Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859495
The ClinicalTrials.gov registry entry for NCT00859495 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00859495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859495 about?
NCT00859495 is a clinical study titled "Trimodal Lung-Sparing Treatment of Pleural Mesothelioma". The primary objective of the study is to determine the feasibility (as determined by lack of serious adverse events) and tolerability (as determined by patient's ability to complete the study) of a multimodal lung sparing regimen of surgery, interpleural and intravenous chemotherapy, and local P-32 ...
What is the current status of trial NCT00859495?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-02. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00859495?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Pemetrexed (DRUG), Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT00859495?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.